Outlook on manufacturing adoptive cell therapies for cancer immunotherapy

Immuno-Oncology Insights 2021; 2(2), 69–72

10.18609/ioi.2021.016

Published: 21 April 2021
Editorial
Xiuyan Wang, Isabelle Rivière

Xiuyan Wang

Associate Director, Michael G. Harris Cell Therapy and Cell Engineering Facility

Isabelle Rivière

Director, Michael G. Harris Cell Therapy and Cell Engineering Facility